Added to YB: 2025-10-28
Pitch date: 2025-10-24
NAGE [bullish]
Niagen Bioscience, Inc.
-15.32%
current return
Author Info
Ridire Research is an independent equity research platform focused on actionable, high-conviction long/short equity ideas. We combine fundamental rigor with quantitative structure to identify mispriced opportunities others overlook. Sign up for the newsletter.
Company Info
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Market Cap
$512.6M
Pitch Price
$7.70
Price Target
N/A
Dividend
N/A
EV/EBITDA
21.10
P/E
27.25
EV/Sales
3.62
Sector
Life Sciences Tools and Services
Category
growth
Niagen Bioscience (NAGE) — Patented Longevity in a Capsule
NAGE: Patented NR compound (Niagen) is only FDA GRAS-approved NAD+ precursor with 100+ studies backing longevity/metabolic benefits. 60%+ gross margins from dual B2B (Nestlé, Thorne) + DTC model. IP moat defended vs competitors; NMN remains unapproved. Risks: NMN category shift, regulatory changes.
Read full article (2 min)